ARTICLE | Clinical News
RHB-104: Ph III MAP US ongoing
January 4, 2017 10:20 PM UTC
In December, Redhill said an independent DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III MAP US trial of twice-daily oral RHB-104 based on a safety revie...
BCIQ Company Profiles